« Return to News | Drug Sponsors

Quest PharmaTech receives $8 million investment for oregovomab trials

Wednesday, June 6, 2012 09:32 AM

Quest PharmaTech, an Alberta-based biotech developing and commercializing products for the treatment of cancer, has received an $8 million investment from parties of South Korea to support its clinical trial programs.

The investment agreement, which ensures funding for the next 12 months, will be used to accelerate the Quest’s ongoing Italian and pending U.S. oregovomab clinical trial, and to re-initiate the anti-MUC1 clinical trial program. Oregovomab is a high affinity monoclonal antibody for the treatment of advanced ovarian cancer that targets the circulating tumor associated antigen CA125.

The agreement also issues up to 15,000,000 common shares to the South Korean parties and undisclosed terms associated with successful commercialization. As the shares to be issued may create a “control person” (an investor holding greater than 20% of Quest's shares), shareholder approval will be sought for the investment arrangement at Quest's upcoming AGM to be held on July 26, 2012.

In the meantime, Quest has received a $500,000 interest free loan from Gi Ho Park, an insider of Quest. As funding under the $8 million investment arrangement is received, Quest will repay the $500,000 bridge loan, or the amount could be converted into Quest's common shares at the higher of $0.40 per share or the market price of Quest's common shares at the time of conversion, less than a 10% discount.

The issuance of Quest common shares will be subject to TSX Venture Exchange approval.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.